Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/47118

TitleGenetic variants as ovarian cancer first-line treatment hallmarks: a systematic review and meta-analysis
Author(s)Assis, Joana
Pereira, Carina
Nogueira, Augusto
Pereira, Deolinda
Carreira, Rafael
Medeiros, Rui
KeywordsOvarian cancer
First-line treatment response
Platinum-based chemotherapy
Clinical Outcome
Genetic Polymorphism
Pharmacogenetic
Issue dateDec-2017
PublisherElsevier
JournalCancer Treatment Reviews
CitationAssis, Joana; Pereira, Carina; Nogueira, Augusto; Pereira, Deolinda; Carreira, Rafael; Medeiros, Rui, Genetic variants as ovarian cancer first-line treatment hallmarks: a systematic review and meta-analysis. Cancer Treatment Reviews, 61, 35-52, 2017
Abstract(s)Background The potential predictive value of genetic polymorphisms in ovarian cancer first-line treatment is inconsistently reported. We aimed to review ovarian cancer pharmacogenetic studies to update and summarize the available data and to provide directions for further research. Methods A systematic review followed by a meta-analysis was conducted on cohort studies assessing the involvement of genetic polymorphisms in ovarian cancer first-line treatment response retrieved through a MEDLINE database search by November 2016. Studies were pooled and summary estimates and 95% confidence intervals (CI) were calculated using random or fixed-effects models as appropriate. Results One hundred and forty-two studies gathering 106871 patients were included. Combined data suggested that GSTM1-null genotype patients have a lower risk of death compared to GSTM1-wt carriers, specifically in advanced stages (hazard ratio (HR), 0.68; 95% CI, 0.48–0.97) and when submitted to platinum-based chemotherapy (aHR, 0.61; 95% CI, 0.39–0.94). ERCC1 rs11615 and rs3212886 might have also a significant impact in treatment outcome (aHR, 0.67; 95% CI, 0.51–0.89; aHR, 1.28; 95% CI, 1.01–1.63, respectively). Moreover, ERCC2 rs13181 and rs1799793 showed a distinct ethnic behavior (Asians: aHR, 1.41; 95% CI, 0.80–2.49; aHR, 1.07; 95% CI, 0.62–1.86; Caucasians: aHR, 0.10; 95% CI, 0.01–0.96; aHR, 0.18; 95% CI, 0.05–0.68, respectively). Conclusion(s) The definition of integrative predictive models should encompass genetic information, especially regarding GSTM1 homozygous deletion. Justifying additional pharmacogenetic investigation are variants in ERCC1 and ERCC2, which highlight the DNA Repair ability to ovarian cancer prognosis. Further knowledge could aid to understand platinum-treatment failure and to tailor chemotherapy strategies.
TypeArticle
DescriptionSupplementary data associated with this article can be found, in the online version, at: https://doi.org/10.1016/j.ctrv.2017.10.001
URIhttp://hdl.handle.net/1822/47118
DOI10.1016/j.ctrv.2017.10.001
ISSN0305-7372
Publisher versionwww.cancertreatmentreviews.com
Peer-Reviewedyes
AccessRestricted access (UMinho)
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_47038_1.pdf
  Restricted access
4,21 MBAdobe PDFView/Open    Request a copy!

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID